186 related articles for article (PubMed ID: 10798821)
1. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study.
Madhusoodanan S; Brenner R; Suresh P; Concepcion NM; Florita CD; Menon G; Kaur A; Nunez G; Reddy H
Ann Clin Psychiatry; 2000 Mar; 12(1):11-8. PubMed ID: 10798821
[TBL] [Abstract][Full Text] [Related]
2. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.
Lambert M; Holzbach R; Moritz S; Postel N; Krausz M; Naber D
Int Clin Psychopharmacol; 2003 Sep; 18(5):251-60. PubMed ID: 12920385
[TBL] [Abstract][Full Text] [Related]
3. Use of olanzapine for elderly patients with psychotic disorders: a review.
Madhusoodanan S; Sinha S; Brenner R; Gupta S; Bogunovic O
Ann Clin Psychiatry; 2001 Dec; 13(4):201-13. PubMed ID: 11958362
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Tran PV; Hamilton SH; Kuntz AJ; Potvin JH; Andersen SW; Beasley C; Tollefson GD
J Clin Psychopharmacol; 1997 Oct; 17(5):407-18. PubMed ID: 9315992
[TBL] [Abstract][Full Text] [Related]
6. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Feldman PD; Kaiser CJ; Kennedy JS; Sutton VK; Tran PV; Tollefson GD; Zhang F; Breier A
J Clin Psychiatry; 2003 Sep; 64(9):998-1004. PubMed ID: 14628974
[TBL] [Abstract][Full Text] [Related]
7. Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study.
Labelle A; Bourget D; Boulay LJ; Ellis J; Tessier P
J Clin Psychopharmacol; 2002 Dec; 22(6):545-53. PubMed ID: 12454553
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
11. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
Kinon BJ; Stauffer VL; McGuire HC; Kaiser CJ; Dickson RA; Kennedy JS
J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
[TBL] [Abstract][Full Text] [Related]
12. An open trial of olanzapine in the treatment of patients with psychotic depression.
Nelson EB; Rielage E; Welge JA; Keck PE
Ann Clin Psychiatry; 2001 Sep; 13(3):147-51. PubMed ID: 11791952
[TBL] [Abstract][Full Text] [Related]
13. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of olanzapine for the treatment of geriatric psychosis.
Hwang JP; Yang CH; Lee TW; Tsai SJ
J Clin Psychopharmacol; 2003 Apr; 23(2):113-8. PubMed ID: 12640211
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
Narendran R; Young CM; Valenti AM; Pristach CA; Pato MT; Grace JJ
J Clin Psychiatry; 2001 Jul; 62(7):509-16. PubMed ID: 11488360
[TBL] [Abstract][Full Text] [Related]
16. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
Costa e Silva JA; Alvarez N; Mazzotti G; Gattaz WF; Ospina J; Larach V; Starkstein S; Oliva D; Cousins L; Tohen M; Taylor CC; Wang J; Tran PV
J Clin Psychopharmacol; 2001 Aug; 21(4):375-81. PubMed ID: 11476121
[TBL] [Abstract][Full Text] [Related]
18. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
